Clinical trials: Crohn Disease of Ileum
Crohn's Disease, Ileitis
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.
- Conditions
- Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Disease, Granulomatous Colitis
- Trial name
- TOSCA (NCT01387594)
- Testing
- lumbar puncture
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Shire
Crohn's Disease
Open Label Extension Study to Protocol C2/13/DR-6MP-02
The open label extension study (Protocol C2/13/DR-6MP-02 EXT) is designed to evaluate the clinical efficacy and safety of 80 mg DR-6MP test formulation for an additional 12 weeks in subjects who already completed 12 weeks of…
- Trial name
- OLE (NCT01433432)
- Testing
- 80 mg DR-6MP
- Sponsor
- Teva GTC
Crohn's Disease
High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times daily for 2 weeks followed by 50…
- Trial name
- NCT00495521
- Testing
- 4-Aminosalicylic acid extended release granules
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Jacobus Pharmaceutical
Crohn's Disease
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP (mercaptopurine) drug (80 mg), as compared to standard…
- Trial name
- NCT01094613
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- 11 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Teva GTC
Crohn's Disease
Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease
The study is being undertaken to evaluate whether delayed-release medications, designed to begin to open in the lower intestinal tract, the main site of Crohn's Disease, are more effective than standard systemically delivered…
- Trial name
- NCT00287170
- Testing
- Delayed Release 6MP or Calcitriol vs. Purinethol
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Teva GTC
Ulcerative Colitis (UC), Crohn Disease (CD)
The Safety and Efficacy of Good Feeling Power® for IBD Patients
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.
- Trial name
- NCT07766733
- Testing
- Good Feeling Power®
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Good Feeling Products GmbH
Fibrostenotic Crohn's Disease
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD).
- Trial name
- NCT07428096
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Palisade Bio
Crohn's Disease
PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's Disease
Using scintigraphic imaging including planar scintigraphy and SPECT, this study will evaluate the utility of two different ex vivo 99mTc-HMPAO labelled mononuclear cell populations in order to select the optimal methodology…
- Trial name
- NCT01051622
- Testing
- Labeling Ceretec
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohns Disease
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
The study is being conducted to evaluate the pharmacokinetic parameters (Cmax, Tmax and AUC) of the new delayed release, lowered dose, 40 mg 6MP test formulation as compared to standard 6MP (100 mg Purinethol) in 12 patients with…
- Trial name
- NCT00774982
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Teva GTC
Crohn's Disease
Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease
A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's…
- Trial name
- NCT01698970
- Testing
- 1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test), 2- excipients (150 mg) in capsule (control)
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Danone Global Research & Innovation Center
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen